focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
I'm in @ average SP 18.19p so I'm at thereabouts 2 bags.
In your experience, would you;
1. Double the stake and increase the average to 36p
2. Sell and take the 2 bags?
3. Sell half?
4. Do nothing and wait?
Thank you very much in advance for your reply.
Wednesday 09 September, 2020
Arkle Resources PLC
Soil sampling results Mine River
RNS Number : 4783Y
Arkle Resources PLC
09 September 2020
9 September 2020
Arkle Resources PLC
("Arkle" or the "Company")
Soil sampling results Mine River
· Soil survey identifies 5 new target areas along the gold trend at Mine River Project
· Licences covering the target areas have been renewed
Arkle Resources (AIM:ARK) is pleased announce the results of the soil sampling survey at their Mine River gold project in the Republic of Ireland. In addition, the two key licence areas that encompass the Tombreen and Knocknalour targets have been renewed.
Five strong gold indicator anomalies have been detected along the gold trend east of Tombreen. A 5km squared area was surveyed using XRF handheld technology obtaining soil samples every 20m along 100m spaced grid lines. At two of the anomalies blue quartz boulders with sulphide minerals similar to that at Tombreen were noted and collected for analysis. Results are expected within three weeks.
A further anomaly was centred around historic finds of gold bearing quartz grading up to 4.1g/t found by RTZ (Rio Tinto Zinc Corp) in the 1980s. Two further anomalies extending south of the sample area will be followed up. Further soil sampling will aim to expand and define these areas. One of the anomalies trends in the same orientation as the Tombreen soil anomaly announced in July 2019 and is of a similar size. Selected soil samples from within this main target will be analysed for gold.
John Teeling commented "Initial results from our ongoing work at Mine River are promising. Sampling, every 20m, using a new technique has, to date, verified two new areas of mineralisation. Ongoing analysis is expected to identify additional areas. The next steps are to drill and/or trench the anomalies."
This announcement has been reviewed and approved by Gavin Berkenheger (CGeol) in his capacity as the Qualified Person for the purposes of the AIM Guidance Note for Mining, Oil and Gas Companies issued by the London Stock Exchange.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
ENDS
Enquiries:
Arkle Resources PLC
John Teeling, Chairman
+353 (0) 1 833 2833
Jim Finn, Finance Director
+353 (0) 1 833 2833
SP Angel Corporate Finance LLP
Nominated Adviser & Joint Broker
Matthew Johnson/Soltan Tagiev
+44 (0) 203 470 0470
First Equity Limited
Joint Broker
Jason Robertson
+44 (0) 207 374 2212
Blytheweigh
+44 (0) 207 138 3204
Megan Ray
Rachael Brooks
Teneo
Mon, 7th Sep 2020 16:22
RNS Number : 2663Y
Arkle Resources PLC
07 September 2020
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:
Arkle Resources plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
X
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
X
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name
Paul and Michelle Johnson
City and country of registered office (if applicable)
4. Full name of shareholder(s) (if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:
7 September 2020
6. Date on which issuer notified (DD/MM/YYYY):
7 September 2020
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached
4.14%
4.14%
291,044,926
Position of previous notification (if
applicable)
7.27%
7.27%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type ofshares
ISIN code (if possible)
Number of voting rightsix
% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
IE00B2357X72 Ordinary Shares
12,036,358
4.14%
SUBTOTAL 8. A
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument
Expirationdatex
Exercise/Conversion Periodxi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument
Expirationdatex
Exercise/Conversion Period xi
Physical or cash
settlementxii
Number of voting rights
% of voting rights
After hours RNS.
News release
Velocys plc
("Velocys" or "the Company")
2 September 2020
Results of Annual General Meeting
Velocys plc (VLS.L), the sustainable fuels technology company, announces that, at its Annual General Meeting held earlier today, all resolutions put to shareholders were duly passed by means of a Poll.
Full details of the resolutions passed are set out in the Notice of Meeting which is available on the Company's website www.velocys.com.
Resolutions
For / Discretion
Against
Total
Vote withheld*
Number
%
Number
%
1. To receive, consider and adopt the annual accounts of the Company as at 31 December 2019 and the Directors' and auditors' reports thereon
387,964,287
95.55
18,080,294
4.45
406,044,581
93,474
2. To re-elect Philip Holland
405,685,377
99.98
95,121
0.02
405,780,498
357,557
3. To re-elect Henrik Wareborn
405,685,377
99.98
93,358
0.02
405,778,735
359,320
4. To re-elect Andrew Morris
405,599,831
99.96
178,904
0.04
405,778,735
359,320
5. To re-elect Sandy Shaw
405,599,831
99.96
178,904
0.04
405,778,735
359,320
6. To re-elect Darran Messem
405,599,831
99.96
178,904
0.04
405,778,735
359,320
7. To re-appoint PricewaterhouseCoopers LLP as auditors to the Company
387,697,101
95.48
18,345,717
4.52
406,042,818
95,237
8. To authorise the Directors to fix the remuneration of the auditors
405,869,404
99.95
184,208
0.05
406,053,612
84,443
9. To authorise the Directors to allot equity securities pursuant to the articles of association of the Company
405,553,088
99.87
531,662
0.13
406,084,750
89,056
10. To authorise the Directors to allot equity securities for cash disapplying pre-emption rights in the Company's articles of association
387,848,826
95.51
18,240,537
4.49
406,089,363
84,443
11. To authorise the Company to purchase its own shares
387,933,203
95.53
18,154,397
4.47
406,087,600
86,206
* 'Vote withheld' is not a vote in law and is not counted in the calculation of the proportion of the votes 'For' and 'Against' a resolution.
- Ends -
For further information, please contact:
Velocys
Henrik Wareborn, CEO
Andrew Morris, CFO
Lak Siriwardene, Head of Communications & Sustainability
+44 1865 800821
Numis Securities (Nomad and joint broker)
Stuart Skinner
+44 20 7260 1000
Canaccord Genuity (Joint broker)
Henry Fitzgerald-O'Connor
James Asensio
+44 20 7523 8000
Radnor Capital (Investor relations)
Joshua Cryer
Iain Daly
+44 20 3897 1830
Field Consulting (PR)
Robert Jeffery
+44 20 7096 7730
Certain information contained in this announcement would hav
01 September 2020
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Exercise of Options and Total Voting Rights
Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 100,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options by an employee.
Application will be made to the London Stock Exchange for the 100,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 7 September 2020.
After Admission, the total number of Ordinary Shares in issue will be 178,453,110 and the total number of voting rights will therefore be 178,453,110 . This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.
Contacts:
Omega Diagnostics Group PLC
Tel: 01259 763 030
Colin King, Chief Executive
www.omegadiagnostics.com
Kieron Harbinson, Group Finance Director
finnCap Ltd
Tel: 020 7220 0500
Geoff Nash / Teddy Whiley (Corporate Finance)
Camille Gochez (ECM)
Walbrook PR Limited
Tel: 020 7933 8780 or omega@walbrookpr.com
Paul McManus
Mob: 07980 541 893
Lianne Cawthorne
Mob: 07584 391 303
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
Yes I agree.
Lots of hype on Hurricane Laura - wall of water going 40 miles in land - come on! It's made land fall, downgraded to cat 3 and the eye is 600 miles away from the drill site, tracking inland north east toward Arkansas. These news channels!
Just gone in for a Friday top up.
Friday 21 August, 2020
Hemogenyx Pharma Plc
Grant of Options
RNS Number : 8331W
Hemogenyx Pharmaceuticals PLC
21 August 2020
21 August 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Grant of Options
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the Board of Directors has agreed to grant options over a total of 5,000,000 ordinary shares of 1p each in the capital of the Company ("Share Options") to the Company's co-founder and CEO Dr Vladislav Sandler.
The details of the Share Options granted are set out below:
Name
Position
Number of Share Options Granted
Exercise Price (pence)
Vesting Date
Expiry Date
Dr Vladislav Sandler
CEO
5,000,000
7
Immediate
19 August 2025
Following the grant of the Share Options there are, in aggregate, 42,465,786 ordinary shares of 1p each in the Company under option held by directors, employees and members of the Scientific Advisory Board of the Company, representing 9.79% of the issued ordinary share capital of the Company.
Enquiries:
Hemogenyx Pharmaceuticals plc
https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder
headquarters@hemogenyx.com
Peter Redmond, Director
peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP
Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Soltan Tagiev
Peterhouse Capital Limited
Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA"):
1.
Details of PDMR/person closely associated with them
a)
Name
Dr Vladislav Sandler
b)
Position/status
CEO, Executive Director
c)
Initial notification/
amendment
Initial notification
2.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument
Options over ordinary shares of 1p of Hemogenyx Pharmaceuticals plc
Identification code GB00BYX3WZ24
b)
Nature of the transaction
Grant of options
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.07
5,000,000
d)
Aggregated information
- Aggregated volume
- Price
Price(s)
Volume(s)
N/A - variable
5,000,000
e)
Date of the transaction
20/08/2020
f)
Place of the transaction
Outside of a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United
Tissue Regenix Group
Holdings in Company
RNS Number : 4706W
Tissue Regenix Group PLC
18 August 2020
TR-1: S tandard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :
Tissue Regenix Group PLC
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
X
An event changing the breakdown of voting rights
Other (please specify)iii:
3. Details of person subject to the notification obligation iv
Name
SPREADEX LTD
City and country of registered office (if applicable)
St Albans, UK
4. Full name of shareholder(s) (if different from 3.) v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi :
17/08/2020
6. Date on which issuer notified (DD/MM/YYYY):
18/08/2020
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights of issuer vii
Resulting situation on the date on which threshold was crossed or reached
5.05%
1.41%
6.46%
7,032,985,756
Position of previous notification (if
applicable)
5.27%
0.04%
5.31%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)
Number of voting rights ix
% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00B5SGVL29
355,260,176
5.05%
SUBTOTAL 8. A
355,260,176
5.05%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument
Expiration
date x
Exercise/
Conversion Period xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
CFD/SPREADBET
99,223,624
1.41%
SUBTOTAL 8. B 1
99,223,624
1.41%
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
I have my Mosman ticket, ready for lift off.
5 August 2020
Mosman Oil and Gas Limited
("Mosman" or the "Company")
Operations Update
Mosman Oil and Gas Limited (AIM: MSMN) the oil exploration, development, and production company, announces an update in respect to operations.
At the Champion Project, site preparation for Falcon-1 is now complete. Drilling is expected to commence shortly once contracts are finalised and the rig is available with drilling operations expected to take a few weeks. The drill results will be made available when received.
At the Greater Stanley Project, the Operator has now submitted all paperwork to the Texas Railroad Commission and this workover is expected to commence shortly.
Mosman is awaiting details on the progress of the Stanley-1 workover from the operator and expects to update the market in due course.
The party that failed to complete the contract to buy the Welch project has issued a claim for the return of the non-refundable deposit paid totalling USD90,000. This claim is considered by Mosman to be invalid.
John W Barr, Chairman, said: "Mosman's focus is on the fully funded Falcon-1 well, and the two funded current workovers, with our clear objective remaining to build the production base."
As announced on 30 July, Mosman is hosting an investor webinar via its joint broker, Monecor UK Limited at 17:00 today, 5 August.
Investors can register using the following link: https://register.gotowebinar.com/register/5907193699015387664
Competent Person's Statement
The information contained in this announcement has been reviewed and approved by Andy Carroll, Technical Director for Mosman, who has over 35 years of relevant experience in the oil industry. Mr. Carroll is a member of the Society of Petroleum Engineers.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have been deemed inside
information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.
Enquiries:
Mosman Oil & Gas Limited
John W Barr, Executive Chairman
Andy Carroll, Technical Director
jwbarr@mosmanoilandgas.com
acarroll@mosmanoilandgas.com
NOMAD and Joint Broker
SP Angel Corporate Finance LLP
Stuart Gledhill / Richard Hail / Soltan Tagiev
+44 (0) 20 3470 0470
Alma PR
Justine James
+44 (0) 20 3405 0205
+44 (0) 7525 324431
mosman@almapr.co.uk
Joint Broker
Monecor (London) Ltd
trading as ETX Capital
Thomas Smith
+44 (0) 20 7392 1432
That was a big buy!!
Fri, 24th Jul 2020 12:38
RNS Number : 0505U
ValiRx PLC
24 July 2020
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Broker Option - Fully Subscribed
London, UK., 24 July 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces that, further to the announcement made at 3.02pm on 23 July 2020, the Broker Option - a facility to allow existing shareholders to participate in the Fundraise on similar terms to the Placing announced, has been fully subscribed for by existing shareholders of the Company.
The Broker Option has raised £300,700 at a price of 7.5 pence per share through the issue of 4,009,334 new ordinary shares.
In the announcement made at 3.02pm on 23 July 2020 the shareholding of Gerry Desler, Chief Financial Officer of the Company, following the Subscription was erroneously stated as 1,941,875 representing 3.6% of the enlarged share capital. The shareholding following the Subscription should have stated 81,667 representing 0.2% of the enlarged share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 7073 2628
www.valirx.com
Suzanne Dilly
Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker)
Duncan Vasey / Lucy Williams / Eran Zucker
Tel: +44 (0) 20 7469 0930
I'm holding for £1.
The news is, 'THE NEWS' is coming!